Valuation: Pulmonx Corporation

Capitalization 53.64M 46.16M 42.2M 40.27M 73.82M 5.15B 75.04M 506M 196M 2.44B 201M 197M 8.51B P/E ratio 2026 *
-1.12x
P/E ratio 2027 * -1.42x
Enterprise value 53.64M 46.16M 42.2M 40.27M 73.82M 5.15B 75.04M 506M 196M 2.44B 201M 197M 8.51B EV / Sales 2026 *
0.59x
EV / Sales 2027 * 0.55x
Free-Float
95.34%
Yield 2026 *
-
Yield 2027 * -
1 day-5.22%
1 week+0.79%
Current month-0.78%
1 month-13.61%
3 months-14.77%
6 months-6.62%
Current year-42.53%
1 week 1.25
Extreme 1.25
1.36
1 month 1.18
Extreme 1.18
1.52
Current year 1.13
Extreme 1.13
2.39
1 year 1.13
Extreme 1.13
3.88
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.81
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 26/10/2025
Director of Finance/CFO 53 30/04/2019
Chief Tech/Sci/R&D Officer - 31/01/2020
Director TitleAgeSince
Director/Board Member 72 31/01/2007
Director/Board Member 64 17/12/2014
Chairman 66 30/09/2019
Change 5d. change 1-year change 3-years change Capi.($)
-5.22%+0.79%-62.97%-89.85% 53.64M
-0.20%+0.03%+14.84%+2.72% 12.68B
+0.07%+0.09%+14.68%+6.28% 9.35B
+2.44%+2.66%+43.75%+25.80% 5.68B
-1.25%+0.21%-2.53%-24.57% 5.46B
+2.15%+0.69%-16.54%+32.52% 4.84B
+0.28%-3.07%-18.66%-11.88% 4.27B
-2.53%-6.66% - - 3.03B
-2.60%-1.73%-1.73%-77.59% 2.04B
-1.92%-6.23%+3.63%-44.65% 1.58B
Average -0.88%-1.37%-2.84%-20.14% 4.9B
Weighted average by Cap. +0.01%-0.53%+8.69%-0.46%

Financials

2026 *2027 *
Net sales 90.87M 78.2M 71.5M 68.22M 125M 8.72B 127M 858M 332M 4.14B 341M 334M 14.42B 98.07M 84.39M 77.16M 73.62M 135M 9.41B 137M 926M 358M 4.47B 368M 360M 15.56B
Net income -47.83M -41.16M -37.63M -35.91M -65.83M -4.59B -66.92M -452M -175M -2.18B -180M -176M -7.59B -38.12M -32.8M -29.99M -28.61M -52.45M -3.66B -53.32M -360M -139M -1.74B -143M -140M -6.05B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
15/05/26 1.270 $ -5.22% 275,275
14/05/26 1.340 $ +0.75% 406,004
13/05/26 1.330 $ +3.10% 282,192
12/05/26 1.290 $ -0.77% 311,606
11/05/26 1.300 $ +3.17% 887,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.270USD
Average target price
5.167USD
Spread / Average Target
+306.82%

Quarterly revenue - Rate of surprise